Experimental Treatment Studies with Cernilton ® in
Human Benign Prostatic Hyperplasia
B. Wagner, U. Otto, H. Becker,
S. Schröder, H. Klosterhalfen
Introduction
Despite the high incidence of benign
prostatic hyperplasia (BPH), so far a conservative treatment modality has not been
established internationally. The reasons for this are the multifactorial etiology of the
symptoms in patients with BPH and the lack of suitable animal models to elucidate the
pathogenesis of BPH. This makes the search for conservative therapies aimed at the
underlying causes of the disease process difficult. Furthermore, all clinical trials in
patients with BPH are complicated by a very strong placebo effect. Currently, patients
with BPH up to stage III according to Vahlensieck are treated conservatively with
phytotherapy in Germany. Read the Full Study